News und Analysen
Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Chemed Corporation’s Board of Directors Authorizes an Additional $300 Million for Stock Repurchase
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has formally authorized an additional $300 million for stock repurchase under Chemed’s existing share repurchase program
2021 Bold Goal Progress Report Shows Humana Medicare Advantage Members Maintained Their Overall Health In 2020, Throughout Pandemic
Humana Inc. (NYSE: HUM) today unveiled its 2021 Bold Goal Progress Report, which details the company’s progress with its ambitious population health strategy launched in 2015 to improve the health
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement
Clovis Oncology Announces At-The-Market Equity Offering Program
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”), under which it may offer and sell, from time
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
Stockholders of Chemed Corporation (NYSE:CHE) today elected a slate of 10 directors at the Company’s 2021 annual stockholders’ meeting. Each of the directors continues from the prior term.
Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare &
Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development
Illumina, Inc. (NASDAQ: ILMN) today announced that it is appointing Susan Tousi as Chief Commercial Officer (CCO), and Dr. Alex Aravanis as Chief Technology Officer (CTO), Head of Research and
Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract
QIAGEN gibt Gründung eines Scientific Advisory Boards und die Tagesordnung der Hauptversammlung im Juni 2021 bekannt
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Gründung eines Scientific Advisory Boards sowie Neuerungen im Aufsichtsrat im Vorfeld der für Juni 2021 geplanten
QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the creation of a Scientific Advisory Board as well as updates on the Supervisory Board ahead of the Annual General Meeting
GenSight Biologics Appoints Françoise de Craecker to its Board of Directors
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Quidel’s QuickVue® At-Home OTC COVID-19 Test Now Available for Sale Through Amazon
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that its
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that on May 11, 2021, the Compensation Committee of the Company’s Board
Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in two upcoming investor conferences:
-
RBC
Savara Reports First Quarter 2021 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the first quarter ending March 31, 2021 and
LivaNova to Present at the UBS Global Healthcare Virtual Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the UBS Global Healthcare Virtual
Simulations Plus to Present at 16th Annual Needham Virtual Technology & Media Conference
Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief
IMV Inc. to Present at Two Upcoming Investor Conferences
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV’s executive management team will be participating in two upcoming investor conferences.
Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Nanobiotix to Present at the UBS Global Healthcare Virtual Conference
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and
Simulations Plus Uplisted to The Nasdaq Global Select Market®
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that